Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | FNTB | P49356 | 3/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5647983 | 1.00 | GRM4 (0.34) | GRM4FAAHFFAR1FNTAFNTB | |
| SCHEMBL5647474 | 0.99 | GRM4 (0.35) | GRM4FAAHFFAR1FNTAFNTB | |
| SCHEMBL5646880 | 0.97 | GRM4 (0.37) | GRM4FFAR1FNTAFNTBTNF | |
| SCHEMBL5653161 | 0.94 | KMT2A (0.35) | GRM4FNTAFNTBKMT2APTPN1 | |
| SCHEMBL5650375 | 0.92 | OPRL1 (0.35) | KMT2AHTR1AHTR6PTPN1 | |
| SCHEMBL5646512 | 0.91 | HTR1A (0.35) | KMT2AEP300HTR1AHTR6PTPN1 | |
| SCHEMBL5650645 | 0.91 | HTR1A (0.35) | KMT2AEP300HTR1AHTR6PTPN1 | |
| SCHEMBL5648950 | 0.91 | HTR1A (0.35) | HTR1AHTR6PTPN1 | |
| SCHEMBL5645746 | 0.91 | HTR1A (0.35) | HTR1AHTR6PTPN1 | |
| SCHEMBL5647961 | 0.91 | HTR1A (0.33) | KMT2AEP300HTR1AHTR6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | GRM4 2699/4885FAAH 2752/4885FFAR1 3667/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | GRM4 3987/4885FAAH 4494/4885FFAR1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.